Search Result

Results for "

AMPA antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Calcium Channel (7) Carbonic Anhydrase (7) Cytochrome P450 (2) GABA Receptor (7) iGluR (75) Isotope-Labeled Compounds (2) MOFs (1) Potassium Channel (7) Reference Standards (10) Sodium Channel (7)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (70)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-15068

NBQX Maximum Cited Publications 20 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-15066

CNQX 15+ Cited Publications FG9065	iGluR	Neurological Disease
CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .

HY-B0122

Topiramate 5+ Cited Publications McN 4853; RWJ 17021	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-15067

DNQX 10+ Cited Publications FG 9041	iGluR	Cancer
DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-15068A

NBQX disodium Maximum Cited Publications 20 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-15066A

CNQX disodium 15+ Cited Publications FG9065 disodium	iGluR	Neurological Disease
CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist . CNQX disodium blocks the expression of fear-potentiated startle in rats .

HY-106467B

Caroverine hydrochloride	iGluR	Neurological Disease
Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .

HY-12506A

Naspm trihydrochloride 5+ Cited Publications 1-Naphthylacetyl spermine trihydrochloride	iGluR	Neurological Disease
Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-12506

Naspm 5+ Cited Publications 1-Naphthylacetyl spermine	iGluR	Neurological Disease
Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-15069

Fanapanel 1 Publications Verification ZK200775; MPQX	iGluR	Neurological Disease
Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.

HY-103234A

GYKI 52466 dihydrochloride	iGluR	Neurological Disease
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .

HY-125931

Unifiram DM232	iGluR	Neurological Disease Inflammation/Immunology
Unifiram (DM232) is a *AMPA* receptor activator and cognitive enhancer. Unifiram activates the *AMPA*-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ ³H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available *AMPA* receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-18663

CP-465022 1 Publications Verification	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-103228

GYKI 53655 hydrochloride LY300168 hydrochloride	iGluR	Neurological Disease
GYKI 53655 (LY300168) hydrochloride is an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.

HY-15072

Zonampanel YM 872	iGluR	Metabolic Disease
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid *(AMPA) receptor*.

HY-18689

SYM2206	iGluR	Neurological Disease
SYM2206 is a potent and non-competitive AMPA receptor antagonist, with an IC₅₀ of 1.6 μM. SYM2206 blocks Na_v1.6-mediated persistent currents .

HY-103233

DNQX disodium salt 10+ Cited Publications FG 9041 disodium salt	iGluR	Cancer
DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-15071

YM90K	iGluR	Neurological Disease
YM90K is a potent and selective AMPA receptor antagonist with a K_i of 84 nM. YM90K is less potent in inhibiting kainate (K_i of 2.2 μM) and NMDA (K_i of 37 μM) receptors. YM90K has neuroprotective actions .

HY-121964

cis-Piperidine-2,3-dicarboxylic acid	iGluR	Neurological Disease
Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions .

HY-15069A

Fanapanel hydrate 1 Publications Verification ZK200775 hydrate; MPQX hydrate	iGluR	Neurological Disease
Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-B0122R

Topiramate (Standard) McN 4853 (Standard); RWJ 17021 (Standard)	Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-19433A

(S)-ATPO	iGluR	Neurological Disease
(S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors .

HY-105860

Selurampanel BGG 492	iGluR	Neurological Disease
Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC₅₀ of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .

HY-19432

UBP-282	iGluR	Neurological Disease
UBP-282 is a potent, selective and competitive *AMPA* and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC₅₀ value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA₂ value of 4.96 .

HY-B0122S

Topiramate-13C6 McN 4853-¹³C₆; RWJ 17021-¹³C₆	Isotope-Labeled Compounds Potassium Channel iGluR Sodium Channel GABA Receptor Carbonic Anhydrase Calcium Channel	Neurological Disease
Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-136905

AMPA receptor antagonist-2	iGluR	Others
AMPA receptor antagonist-2 (example 23) is an AMPA receptor antagonist .

HY-145959

AMPA receptor antagonist-3	iGluR	Neurological Disease
AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .

HY-114975

EGIS-8332	iGluR	Neurological Disease
EGIS-8332 is a non-competitive *AMPA* receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC₅₀ = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease .

HY-176297

Tezampanel etibutil	AMPK iGluR	Neurological Disease
Tezampanel etibutil is an orally active *AMPA/GluR* antagonist. Tezampanel etibutil can be used in the research of pain, migraine, and neurological disorders .

HY-136844

LY-300168 GYKI 53655	iGluR	Neurological Disease
LY 300168 (GYKI 53655) is a non-competitive, blood-brain-barrier permeable AMPA receptor antagonist. LY 300168 attenuates hippocampal injury. LY 300168 blocks the sound-induced clonic and tonic convulsions .

HY-15068AR

NBQX disodium (Standard) FG9202 disodium (Standard)	iGluR Reference Standards	Neurological Disease
NBQX (disodium) (Standard) is the analytical standard of NBQX (disodium). This product is intended for research and analytical applications. NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-110234

Topiramate D12 McN 4853 D12 ; RWJ 17021 D12	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-100785A

gamma-DGG acetate γDGG acetate; γ-D-Glutamylglycine acetate	iGluR	Neurological Disease
gamma-DGG acetate (γDGG acetate) is a competitive AMPA receptor blocker. gamma-DGG acetate is also a reversible Excitatory post-synaptic potentials (e.p.s.p.s) antagonist .

HY-124539

ZK 187638	iGluR	Neurological Disease
ZK 187638 is an AMPA receptor antagonist. ZK 187638 antagonizes the kainate-induced currents in cultured hippocampal neurons with an IC₅₀ of 3.4 μM in a noncompetitive fashion .

HY-W922811

DL-Willardiine	iGluR	Neurological Disease
DL-Willardiine is an *AMPA* antagonist with an IC₅₀ of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research .

HY-139350

AMPA receptor antagonist-1	iGluR	Neurological Disease
AMPA receptor antagonist-1 (Example 143) is an *AMPA* receptor antagonist. AMPA receptor antagonist-1 can be used in the research of neurological disorders .

HY-100815

(R)-AMPA	iGluR	Neurological Disease
(R)-AMPA is an inactive AMPA receptor ligand that inhibits the release of excitatory amino acids from neurons. (R)-AMPA is inactive in experiments that enhance the release of [3H]D-aspartate induced by electrical stimulation. (R)-AMPA is inhibited by competitive and noncompetitive AMPA receptor selective antagonists in response to AMPA and glutamate .

HY-15070

YM 900	iGluR	Neurological Disease
YM 900 is an AMPA receptor antagonist .

HY-129030

BDZ-g	iGluR	Neurological Disease
BDZ-g is a potent, selective antagonist of *AMPA* receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .

HY-15073

Becampanel AMP 397	iGluR	Neurological Disease
Becampanel (AMP397) is the first competitive *AMPA* antagonist and an antiepileptic agent.

HY-107519

(R)-3,4-DCPG	iGluR	Neurological Disease
(R)-3,4-DCPG is an *AMPA* and NMDA antagonist with a K_d of 77 μM for AMPA. (R)-3,4-DCPG complete antagonizes the NMDA-induced depolarization at a concentration of 500 μM. (R)-3,4-DCPG exhibits a weak antagonistic effect on kainate-induced depolarizations .

HY-106039

LY 215490	iGluR	Neurological Disease
LY 215490 is a selective, competitive AMPA receptor antagonist against *AMPA, CGSl9755* and kainate with IC₅₀ values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-118814

YM928	iGluR	Neurological Disease
YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid *(AMPA) receptor* antagonist. YM928 inhibits AMPA receptor-mediated toxicity in primary rat hippocampal cultures with an IC₅₀ value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC₅₀ value of 3 μM and antagonizes AMPA-induced inward currents with an IC₅₀ value of 1 μM. YM928 is promising for research of neurological disorders .

HY-107603

NS3763	MOFs iGluR	Neurological Disease
NS3763 is a selective and noncompetitive GLU_K5 receptor antagonist with an IC₅₀ of 1.6 µM. NS3763 does not show significant antagonistic properties on GLU_K6, AMPA or NMDA receptors .

HY-18663B

CP-465022 hydrochloride	iGluR	Neurological Disease
CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663A

CP-465022 maleate	iGluR	Neurological Disease
CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-117176

KRP-199	iGluR	Neurological Disease
KRP-199 (compound 14h) is an α-amino-3-hydroxy-5-methylisoxazolepropionic acid receptor (AMPA-R) antagonist (K_i=16 nM) with high potency and selectivity for *AMPA-R* in vitro and good neuroprotective effects in vivo. KRP-199 can be used in the study of neurodegenerative diseases .

HY-107518

(R,S)-3,4-Dicarboxyphenylglycine (R,S)-3,4-DCPG	iGluR	Neurological Disease
(R,S)-3,4-Dicarboxyphenylglycine ((RS)-3,4-DCPG) is an *AMPA* receptor antagonist. (R,S)-3,4-Dicarboxyphenylglycine antagonizes AMPA-mediated depolarization of motor neurons in neonatal rats. (R,S)-3,4-Dicarboxyphenylglycine can be used in the study of neurological diseases .

Cat. No.	Nombre del producto	Chemical Structure

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-B0122S1

Topiramate-13C

Topiramate- ¹³C (McN 4853- ¹³C) is ¹³C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: